Stoffels ushered in half a dozen blockbusters for J&J

Paul Stoffels is retiring from J&J after a nearly two-decade run in which he advanced an innovative pipeline that yielded multiple blockbusters, drove the company’s investment in early stage projects and emphasized global public health.

Stoffels has been CSO of Johnson & Johnson (NYSE:JNJ) since 2012, and has held positions overseeing its pharmaceuticals division and global R&D. After an initial stint with the pharma’s Janssen Pharmaceutica unit in the 1990s, he returned to J&J in 2002 following its $320 million acquisition of HIV company Tibotec-Virco Group N.V., where he was CEO of Virco and chairman of Tibotec...